IGC Pharma
25 hedge funds and large institutions have $1.11M invested in IGC Pharma in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
18% more capital invested
Capital invested by funds: $943K → $1.11M (+$167K)
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.18% less ownership
Funds ownership: 3.57% → 3.39% (-0.18%)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$75.8K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$52.5K |
| 3 |
VF
Virtu Financial
New York
|
+$23.1K |
| 4 |
State Street
Boston,
Massachusetts
|
+$22.7K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$17.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$57K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$11.7K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$7.55K |
| 4 |
BlackRock
New York
|
-$5.79K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.8K |
IGC Hedge Fund Activity: Q2 2024 in Review
25 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q2 2024, worth a combined $1.11M — up 18% from $943K a quarter earlier.
Fund positioning in IGC was balanced in Q2 2024: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 6 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $75.8K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $57K sold.
- 25 institutional investors held IGC Pharma (IGC) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $1.11M of IGC Pharma stock for Q2 2024, up 18% quarter-over-quarter.
- 5 funds opened new IGC Pharma positions in Q2 2024 and 5 closed out, a net change of 0 holders.
- The largest IGC Pharma buyer in Q2 2024 was Susquehanna International Group, an estimated $75.8K added.
- The largest IGC Pharma seller in Q2 2024 was Renaissance Technologies, an estimated $57K sold.
Based on aggregated 13F filings for Q2 2024.